These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32811232)

  • 1. The effects of progesterone treatment on nuchal translucency in women with threatened miscarriage.
    Karadağ C; Yoldemir T; Demircan S; Çalışkan E
    J Obstet Gynaecol; 2021 May; 41(4):601-604. PubMed ID: 32811232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of exogenous oral micronized progesterone on first trimester aneuploidy screening markers in women with threatened miscarriage: a matched case control study.
    Karaca I; Erdoğan ŞV; Doğan K; Alay I; Ince O; Yıldırım Karaca S; Comba C; Bahceci E; Erdoğan A; Ozturk E; Ekin M
    J Matern Fetal Neonatal Med; 2022 Apr; 35(7):1224-1229. PubMed ID: 32456488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does progesterone therapy increase nuchal translucency in women with threatened miscarriage?
    Keçecioğlu M; Tokmak A; Keçecioğlu TS; Akselim B; Karakaya BK; Taşçı Y
    Ginekol Pol; 2016; 87(5):390-4. PubMed ID: 27304657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
    Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
    Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
    Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
    Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
    Spencer K; Cowans NJ; Avgidou K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Normal range of intracranial translucency in healthy Turkish pregnancies and its association with first trimester maternal serum biochemistry and ductus venosus pulsatility index. .
    Artunc-Ulkumen B; Pala HG; Uyar Y; Bulbul-Baytur Y; Koyuncu FM
    Ginekol Pol; 2014 Oct; 85(10):738-41. PubMed ID: 25546923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of dydrogesterone treatment on first-trimester aneuploidy screening markers and nuchal translucency in women with threatened miscarriage.
    Yıldız E; Timur B
    Turk J Obstet Gynecol; 2023 Mar; 20(1):16-21. PubMed ID: 36908009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of exogenous progesterone on fetal nuchal translucency: an observational prospective study.
    Giorlandino C; Cignini P; Padula F; Giannarelli D; d'Emidio L; Aloisi A; Plotti F; Angioli R
    Am J Obstet Gynecol; 2015 Mar; 212(3):335.e1-7. PubMed ID: 25305408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
    Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
    Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy.
    Spencer K; Cicero S; Atzei A; Otigbah C; Nicolaides KH
    Prenat Diagn; 2005 Oct; 25(10):927-9. PubMed ID: 16088864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First trimester risk assessment for trisomy 21 in twin pregnancies combining nuchal translucency and first trimester biochemical markers.
    Prats P; Rodríguez I; Comas C; Puerto B
    Prenat Diagn; 2012 Oct; 32(10):927-32. PubMed ID: 22752980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reference centile charts of first-trimester aneuploidy screening & Doppler parameters for Indian population.
    Kumar M; Singh S; Sharma K; Singh R; Ravi V; Gupta U; Bhattacharjee J
    Indian J Med Res; 2018 Oct; 148(4):427-434. PubMed ID: 30666005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
    Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (β-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy.
    Ziolkowska K; Tobola-Wrobel K; Dydowicz P; Zurawski S; Pietryga M; Wysocka E
    Ginekol Pol; 2020; 91(12):748-754. PubMed ID: 33447994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight heparin and first trimester maternal PAPP-A and hCG levels, fetal nuchal translucency in the first trimester of pregnancy.
    Tarim E; Cok T; Hacivelioglu S; Bagis T
    Clin Exp Obstet Gynecol; 2011; 38(1):81-3. PubMed ID: 21485734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.